modelC01CE01

Diagram of C01CE01

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Amrinone
ATC code:C01CE01
route:intravenous
compartments:2
dosage:15mg
volume of distribution:0.7L
clearance:4.6ml/min/kg
other parameters in model implementation

Amrinone is a phosphodiesterase III inhibitor with inotropic and vasodilatory effects, formerly used in the management of congestive heart failure. It increases cardiac contractility and induces vasodilation. Due to safety concerns (notably thrombocytopenia), its use has largely been superseded by other agents and it is not commonly used in clinical practice today.

Pharmacokinetics

Pharmacokinetics in adult patients with congestive heart failure after intravenous administration.

References

  1. Allen-Webb, EM, et al., & Banner, W (1994). Age-related amrinone pharmacokinetics in a pediatric population. Critical care medicine 22(6) 1016–1024. DOI:10.1097/00003246-199406000-00022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8205809

  2. Bailey, JM, et al., & Hug, CC (1991). Pharmacokinetics of amrinone during cardiac surgery. Anesthesiology 75(6) 961–968. DOI:10.1097/00000542-199112000-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1741517

  3. Eason, CT, et al., & Bonner, FW (1988). The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. European journal of drug metabolism and pharmacokinetics 13(2) 129–133. DOI:10.1007/BF03191314 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3145204

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)